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Abstract
Mesenchymal stem cells (MSC) are cells of stromal 
origin which exhibit unlimited self-renewal capacity and 
pluripotency in vitro . It has recently been observed that 
MSC may also exert a profound immunosuppressive 
and anti-inflammatory effect both in vitro  and in 
vivo  with consequent potential use in autoimmune 
disorders. We present the case of a patient suffering 
from childhood-onset, multidrug resistant and steroid-
dependent Crohn’s disease who underwent systemic 
infusions of MSC, which led to a temporary reduction 
in CCR4, CCR7 and CXCR4 expression by T-cells, and 
a temporary decrease in switched memory B-cells, 
In addition, following MSC infusion, lower doses of 
steroids were needed to inhibit proliferation of the 
patient’s peripheral blood mononuclear cells. Despite 
these changes, no significant clinical benefit was 
observed, and the patient required rescue therapy with 
infliximab and subsequent autologous hematopoietic 
stem cell transplantation. The results of biological 
and in vitro  observations after MSC use and the 
clinical effects of infusion are discussed, and a brief 
description is provided of previous data on MSC-based 
therapy in autoimmune disorders. 
Key words: Autoimmune disease; Crohn’s disease; 
Interferon-γ pretreatment; Mesenchymal stem cells; 
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Core tip: This is the first report of a lack of clinical 
response using interferon-γ pre-treated mesenchymal 
stem cell infusion in a patient with intractable Crohn’
s disease. Data on the clinical effects of mesenchymal 
stem cell treatment in autoimmune disorders are 
sparse and usually report a good clinical response; 
however, since very few reports have been published, 
we think negative results are also worthy of attention. 
The use of mesenchymal stem cells pre-treated with 
interferon-γ is also of interest, and the lack of clinical 
benefit of bone marrow-derived interferon-γ pre-
treated mesenchymal stem cell infusion has also been 
described, despite the lymphocyte immune regulation 
effect.
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INTRODUCTION
Mesenchymal stem cells (MSC) are cells of stromal 
origin which exhibit unlimited self-renewal capacity and 
pluripotency in vitro; more specifically, several reports 
have described the capacity of MSC to differentiate 
in vitro into multiple cellular lineages, and their 
use in regenerative medicine has been extensively 
investigated in various clinical settings[1].
Much interest has been generated recently by the 
observation that MSC may also exert a pronounced 
immunosuppressive and anti-inflammatory effect, 
both in vitro and in vivo. The mechanisms behind this 
immunosuppressive effect are still unclear, but they 
seem to involve events mediated by both soluble 
factors and cell contact[2,3].
There are few studies describing treatment with 
systemic MSC in humans, and most of these are 
in patients treated for acute graft-vs-host disease 
(GvHD), indicating that infusions of MSC expanded in 
vitro, irrespective of the donor, might be an effective 
treatment for patients with steroid-resistant, acute 
GvHD[4]. MSC treatment has also been tried out in 
other autoimmune diseases such as systemic lupus 
erythematosus and Sjögren’s disease[5,6], with encou-
raging results. Moreover, it has been demonstrated 
that systemic infusions of MSC lessen the clinical 
and histopathological severity of experimental colitis, 
reducing weight loss, diarrhea, and inflammation[7]. 
This potential role of MSC in modulating the immune 
response and tissue regeneration led to the idea of 
using MSC for a new cellular approach in the treatment 
of Crohn’s disease (CD) in humans, with conflicting 
results[8]. Preclinical data obtained from cellular and 
animal models have suggested that the profile of 
immune activation in the host prior to administration of 
MSC can be a critical factor in the outcome of immune 
suppression. Indeed, treatment with interferon-γ 
(IFN-γ) can enhance the immunosuppressive action 
of MSC, especially when the MSC are used in a 
setting of ongoing immune activation[9], and several 
reports have suggested that exposure to activated 
lymphocytes, or to IFN-γ, is necessary to activate the 
immunosuppressive properties of MSC[10-12]. Based 
on these results, we hypothesized that MSC could be 
briefly incubated with IFN-γ in a clinical-grade setting 
in order to improve their capability for treating severe 
immune disorders. We present the case of a patient 
with intractable, childhood-onset, steroid-dependent 
CD, who underwent MSC infusion to no effect.
CASE REPORT
The patient was a 31-year-old woman suffering from 
CD. This diagnosis was made when she was 11 years 
old, and was characterized by diarrhea, weight loss, 
asthenia, and high levels of inflammatory markers. 
On that occasion, colonoscopy and esophagogastro-
duodenoscopy were performed and biopsy specimens 
confirmed the preliminary diagnosis of ileal and perianal 
CD.
The patient was initially treated with steroids 
and enteral nutrition, but frequent relapses occurred 
when steroids were tapered leading rapidly to ileo-
colic resection due to stenosis. As a consequence, 
thalidomide was started and there was some clinical 
improvement, but treatment was suspended when 
the patient showed evidence of thalidomide-related 
peripheral toxicity. Over the following years, several 
attempts were made to treat her with azathioprine, 
cyclosporine, and methotrexate, but the clinical 
response was poor. When she was 24 years old, she 
received treatment with infliximab, with some clinical 
improvement, but she then developed a new stenosis 
requiring surgical procedures and the drug was 
withdrawn. She was then started on adalimumab, but 
no clinical benefits were observed and she developed 
herpetic esophagitis. A second trial with thalidomide 
was suspended because of the re-appearance of 
neurological complications and dapsone was eventually 
started, on the basis of some anecdotal clinical reports, 
again with a poor clinical response.
Given the long clinical history, characterized by 
numerous complications and multiple surgical inter-
ventions, a disease that was steroid-dependent and 
still active, despite ample use of immunosuppressants, 
and the absence of opportunistic infections and small 
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intestine bacterial overgrowth, we decided to try MSC 
infusions. 
At the time of the first infusion, the physical exa-
mination was unremarkable, but the patient had oral 
ulcers with a feeding inability requiring nocturnal 
enteral nutrition, abdominal pain, watery diarrhea (35 
episodes per week), and perianal ulcers. Colonoscopy 
showed inflammation of the mucosa. Laboratory 
examinations were normal, including acute phase 
reactants (erythrocyte sedimentation rate: 18 mm/h; 
normal value 0-20; C-reactive protein: 0.34 mg/dL; 
normal value < 0.5) except for the presence of chronic 
normocytic anemia (hemoglobin: 9.2 g/dL; mean cell 
volume: 78 fl), hypergammaglobulinemia (IgG: 1780 
mg/dL) and increased levels of fecal calprotectin (2200 
mg/kg; normal value < 50). Magnetic resonance 
imaging of the gastrointestinal tract showed free 
fluid, peritoneal fat stranding with enhancement, 
diffuse thickening of the bowel wall, and stratified 
enhancement of sigmoid and ascending colon; ileal 
and ileo-colic strictures were also present. The CD 
activity index (AI) was 270. The patient was treated 
with dapsone (50 mg bid) and prednisone (25 mg/d).
The patient underwent the two scheduled MSC 
infusions (2 × 106 cells/kg per infusion) which were 
well tolerated. Ten days after the second infusion, 
despite CDAI improvement (215), there was exacer-
bation of abdominal pain and worsening of diarrhea, 
and the clinical picture deteriorated rapidly. Laboratory 
examinations remained normal, but calprotectin levels 
were still high, and the patient underwent rescue 
therapy with infliximab (10 mg/kg per infusion) with 
transient slight improvement; she was then directed to 
an autologous hematopoietic stem cell transplantation 
(HSTC) program.
The MSC were produced in the officially approved cell 
factory Laboratorio di Terapia Cellulare e Genica “Stefano 
Verri” in Monza (Italy), compliant with European good 
manufacturing practices, as determined by AIFA (Agenzia 
Italiana del Farmaco, Rome). The procedures were 
approved by the Istituto Superiore di Sanità (approval by 
ISS, Rome, 5.09.2007, n 45253(06)-PRE.21-882).
The medical ethical committee of the IRCCS “Burlo 
Garofolo” (Trieste, Italy) approved the use of IFN-γ 
pretreated MSC for compassionate use. The patient 
gave her written informed consent.
DISCUSSION
We present a case of refractory, drug-resistant, steroid-
dependent childhood-onset CD which was then treated 
with two infusions of MSC, with rapid deterioration of 
the clinical picture and subsequent need for medical 
rescue therapy before autologous HSTC.
To our knowledge, this is the 15th patient affected 
by CD to be treated with systemic MSC infusion. 
The first report is by Duijvestein et al[8], in which 10 
patients with chronic severe steroid-refractory CD 
were recruited for MSC treatment in a two-infusion 
protocol schedule. Two patients were withdrawn from 
the study and did not complete the protocol. Among 
the 8 patients who received both infusions, 5 showed 
improvement in the CDAI, but only 3 showed a clinical 
response (defined as a drop in CDAI by more than 
70), while 3 patients required surgery over a 14-wk 
period following infusions. It should be pointed out 
that remission was not achieved in any of the patients. 
Liang et al[9] treated 7 patients, of whom 4 had CD and 
3 ulcerative colitis. According to the authors, 5 patients 
had achieved remission at the 3-mo follow-up, and 
this remission lasted for over 24 mo in 2 patients. 
However, only one patient stopped steroid treatment 
completely, while 3 patients tapered partially and the 
other 3 could not reduce their total steroid dosage, an 
indirect indication of incompletely controlled disease.
In the current case, there was no observable clinical 
improvement after infusion, and indeed, soon after the 
second infusion, the patient required rescue therapy 
with infliximab before undergoing HSCT. We would 
also like to stress that in order to enhance the clinical 
response in our patient, the MSCs were pre-treated 
with IFN-γ, because it has been shown that IFN-γ 
activation of MSCs increases their immunosuppressive 
capabilities in vitro and (we therefore hoped), their 
therapeutic efficacy in vivo[13]. Unfortunately, we found 
no evidence of any positive clinical response.
It might be argued that the lack of clinical response 
to MSC infusion in our case could be due to weak 
biological properties of the cells. It should be pointed out 
that when the cells were thawed after cryopreservation 
before their infusion, a small sample was analyzed to 
check MSC vitality and immunosuppressive capacity: no 
difference was found before and after cryopreservation. 
In addition, a much higher percentage of natural killer 
(NK) cells was found in the patient’s serum after the 
second infusion (4.52% before infusion, compared 
to 14.5% after, which could be interpreted as a 
“physiological” response to MSC infusion. In fact, it is 
known that MSC are susceptible to lysis by NK cells, 
and that there is a natural tendency for NK cells to 
proliferate in order to counteract the biological effect of 
MSC[14]. 
Another interesting finding which confirmed the 
biological effect of MSC infusion was that methyl-
prednisolone IC50 levels (i.e., the concentration 
required to reduce in vitro mononuclear proliferation to 
50%) were similar before MSC treatment (T-7 and T0), 
while lower concentrations of the steroid were needed 
to inhibit proliferation of the patient’s peripheral blood 
mononuclear cells after infusion (T+7 and T+14). After 
the last infusion, however (T+28), an increase in the 
IC50 was observed which coincided with the patient’s 
worsening symptoms (Figure 1)[15].
Analysis of T-lymphocytes before the infusion and 
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at days +2 and +7 respectively showed a transient 
reduction in CCR4, CCR7 and CXCR4 expression at 
day +2 compared with basal levels, while expression 
of CXCR4 was still reduced after 7 d (Figure 2). 
In addition, analysis of B-cells showed a transient 
decrease in switched B-cells, while the maturation 
of monocyte-derived dendritic cells, as measured by 
analysis of CD80, CD86, and CD83 expression, was 
not affected (data not shown). These results suggest 
that MSC infusion may have led to a mobilization of 
select T and B cell subsets to tissues within 2 d; these 
observations support previous reports suggesting a 
mechanism of B-cell suppression, with immunoglobulin 
impairment production induced by release of soluble 
factors[16]. 
In our case, despite the evidence of some in vitro 
properties and in vivo biological effects, no positive 
clinical response to MSC therapy was found. Of course, 
this is just a single case report and large multicenter 
trials, presently ongoing, need to be encouraged[17]. 
We should also stress the fact that MSCs were used in 
this case to treat a very severe form of CD, resistant 
to multiple attempts with standard treatments, and in 
a late phase of clinical progression. Studies of GvHD 
patients after allogeneic HSCT seem to support the 
hypothesis that MSC therapy should be promoted 
in the very early stage of disease immediately after 
steroid failure, while patients with more advanced or 
chronic GvHD failed to show any clinical benefit[18]. In 
line with this observation, we recently demonstrated 
that mediators derived from activated lymphocytes 
can suppress MSC which have not been previously 
activated[19]. In fact, the presence of soluble mediators 
in the environment can be a critical factor in the 
survival and action of MSC[20,21]. IFN-γ treatment has 
been proposed to enhance the action of MSC against 
already-activated lymphocytes, but this treatment 
may not to be sufficient to protect MSC from the effect 
of high concentrations of inflammatory mediators. 
Therapy with MSC has created great hope for advances 
in the treatment of autoimmune disorders, but at this 
moment in time, there is still only weak evidence of 
their clinical effectiveness. In fact, there is a great 
paucity of data available regarding clinical trials with 
MSC therapy in the field of autoimmune disorders. 
To confirm this, a PubMed search was carried out 
for the following terms “autoimmune disorders” and 
“mesenchymal stem cells”. We found 485 articles, 
consisting mostly of reviews (177/485; 36.5%) and 
animal models and in vitro studies (285/485; 58.8%), 
while there were only 23 articles consisting of clinical 
trials and case reports (4.7%). 
It is also important to bear in mind that negative 
findings tend not to be reported in the medical 
literature, which is why we think that describing this 
experience should be of interest to other physicians 
and researchers. Clearly, the data in our possession 
is still insufficient to be able to consider systemic 
infusion of MSC in the treatment of CD, at least in 
its very advanced, progressive and multiple drug-
resistant forms. Our experience suggests that patients 
with intractable drug-resistant CD should still undergo 
HSCT, while MSC therapy may perhaps be considered 
in the earlier stages of the disease. The use of MSC 
therapy in CD fistulas, on the other hand, may be of 
some benefit[22].
COMMENTS
Case characteristics
After a long series of attempts at treatment with immunosuppressants and 
surgery, a 31-year-old woman with intractable Crohn’s disease presented with 
oral ulcers, a feeding inability requiring nocturnal enteral nutrition, abdominal 
pain, watery diarrhea and perianal ulcers.
Clinical diagnosis
The diagnosis was Crohn’s disease.
Differential diagnosis
Given the clinical history of the patient, characterized by numerous 
complications, a series of surgical interventions, a dependency on steroids, and 
long-term use of immunosuppressants, we ruled out the possible presence of 
opportunistic infections, malignancies and small intestine bacterial proliferation.
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Figure 1  Increase in methylprednisolone IC50 coincided with worsening 
symptoms. Concentration of methylprednisolone that inhibited 50% of the 
proliferation (IC50) of peripheral mononuclear blood cells obtained from the 
patient at various experimental times, before and after mesenchymal stem 
cells infusion (arrows). Inhibition of proliferation was determined by labelling 
metabolically active cells (stimulated with concanavalin-A) with [methyl-
3H]thymidine [12].
Figure 2  Time course of CCR7, CCR4 and CXCR4 expression by 
T-lymphocytes. Analysis of CCR7, CCR4 and CXCR4 expression by flow 
cytometry showed a transient reduction after 2 d. Expression levels were 
measured as mean fluorescence intensity index. 
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Laboratory diagnosis
The patient had chronic normocytic anemia (Hb: 9.2 g/dL; MCV: 78 fl), 
hypergammaglobulinemia (IgG: 1780 mg/dL) and increased levels of fecal 
calprotectin (2200 mg/kg; n.v. < 50).
Imaging diagnosis
The patient underwent magnetic resonance imaging of the gastrointestinal tract, 
which showed free fluid, peritoneal fat stranding with enhancement, diffuse 
thickening of the bowel wall, and stratified enhancement of the sigmoid and 
ascending colon; ileal and ileo-colic strictures were also found.
Pathological diagnosis 
Biopsy specimens from both the colon and ileum were consistent with a 
diagnosis of ileal and perianal Crohn’s disease.
Treatment
Interferon-γ pre-treated mesenchymal stem cells were infused at a dosage of 2 
× 106 cells/kg. Two infusions were scheduled.
Term explanation
Mesenchymal stem cells are cells of a stromal origin which exhibit unlimited 
self-renewal capacity and pluripotency in vitro and have a pronounced anti-
inflammatory and immunosuppressive effect.
Experiences and lessons
We describe a case of a patient with intractable Crohn’s disease in which 
no clinical benefit was obtained from the use of interferon-γ pre-treated 
mesenchymal stem cells despite lymphocyte dysregulation. The usefulness 
of mesenchymal stem cell treatment in autoimmune disorders is still to be 
confirmed; the literature is scarce and results are uncertain.
Peer-review
The authors describe a case of intractable Crohn’s disease which failed to 
respond to parenteral mesenchymal stem cell therapy. The article highlights 
the failure of interferon-γ pre-treated mesenchymal stem cell infusion, points to 
the effect on lymphocyte regulation and discusses the results obtained using 
mesenchymal stem cells to treat autoimmune diseases.
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